ARCA Biopharma ($ABIO) announced its net loss for the year 2016 at $16.4 million, or $1.81 per share, for 2016 compared to $11.4 million, or $1.82 per share, for 2015. Its total operating expenses for the year were $16.6 million compared to $11.5 million in 2015. ARCA closed the year with $23.5 million in cash, cash equivalents and marketable securities. The company believes that the balance would sufficient to fund its operations, at its projected cost structure, through the end of 2017.
Imprimis Pharmaceuticals ($IMMY) reported a loss of $6.1 million in its fourth quarter. On a per-share basis, the San Diego-based company suffered a loss of $0.44. Its revenue for the quarter stood at $5.8 million. For the entire year, Imprimis reported its loss at $19.1 million, or $1.50 per share. Revenue was reported as $19.9 million.